ACP-105 Benefits: What the Research Actually Shows

Key takeaways

What Is ACP-105?

ACP-105 is a non-steroidal selective androgen receptor modulator (SARM) that was nominated as a development candidate by Acadia Pharmaceuticals in February 2006, the company's first program targeting a nuclear hormone receptor rather than the central nervous system indications it typically pursued.

Chemically, ACP-105 is a benzonitrile derivative. Analytical chemistry papers written for anti-doping purposes identify it as 2-chloro-4-[(3-endo)-3-hydroxy-3-methyl-8-azabicyclo[3.2.1]oct-8-yl]-3-methylbenzonitrile. This puts it in a different chemical family from several other research SARMs it is sometimes casually grouped with online; a 2011 pharmacology review that surveyed several tissue-selective SARM candidates classified ACP-105 as a benzonitrile alongside structurally distinct compounds such as the naphthalenecarbonitrile AC-262536 and the pyrroloquinolinone LGD-3303, underscoring that these molecules share a design goal (tissue-selective androgen receptor activation) rather than a common scaffold.

Two different CAS registry numbers appear across the literature: chemical vendors such as Cayman Chemical list ACP-105 under CAS 899821-23-9, while recent computational toxicology papers register it under CAS 1048998-11-3. This inconsistency reflects the limited, non-standardized documentation available for a compound that was never advanced to a marketed drug.

ACP-105 has not been approved by the FDA or any other regulatory authority for any medical use. One vendor description explicitly states that it is not approved by the FDA for human use and is sold primarily through research-chemical websites rather than supplement retailers.

What Do the Animal Studies Show About Muscle and Bone Effects?

The original rationale for ACP-105 came from preclinical work Acadia Pharmaceuticals presented at the Experimental Biology 2008 meeting, in a poster titled "In Vitro and In Vivo Profile of a Novel Tissue Selective, Orally Bioavailable Non-Steroidal Androgen Receptor Modulator." The company's own summary states that ACP-105 was shown to be as potent and efficacious as testosterone in in vitro assays without interaction at other hormone receptors, and that it demonstrated potent anabolic effects on muscle and bone with minimal effect on the prostate in preclinical models.

This description is consistent with the general logic of SARM development: producing androgen-receptor activation in muscle and bone while limiting stimulation of the prostate, which is the property that in principle distinguishes SARMs from testosterone and classical anabolic-androgenic steroids.

It is important to be precise about what this evidence actually consists of. The 2008 material is a conference poster summary released through a company press announcement, not a full peer-reviewed manuscript with dose-response data specific to ACP-105. A related Acadia compound, AC-262536, did receive this kind of detailed, peer-reviewed characterization, including a 2-week chronic study in castrated rats showing significant stimulation of levator ani growth and suppression of luteinizing hormone alongside weak effects on prostate and seminal vesicle weight, published in the Journal of Steroid Biochemistry and Molecular Biology. No equivalent peer-reviewed manuscript reporting comparable quantitative dose-response, luteinizing hormone, or prostate-weight data specifically for ACP-105 was identified in this review. Claims circulating on vendor and forum sites that quantify ACP-105's anabolic effect as a specific fraction of dihydrotestosterone's maximal response could not be traced to a peer-reviewed source and should be treated as unverified.

In short, the muscle- and bone-related claims for ACP-105 rest on a single industry-reported preclinical summary rather than an independently replicated body of published data, and no musculoskeletal outcome trial in humans exists to confirm whether these animal findings would translate to people.

Does ACP-105 Have Cognitive or Neuroprotective Effects?

Separate from its anabolic profile, ACP-105 has been examined in a small number of rodent neuroscience studies, because androgen receptor signaling is known to influence cognition and brain injury responses in some animal models.

A 2011 study in Brain Research examined ACP-105 in female mice that were either sham-irradiated or exposed to whole-body ionizing radiation (10 Gy of cesium-137) as a model of radiation-induced cognitive impairment. Irradiation impaired sensorimotor function in vehicle-treated mice but not in ACP-105-treated mice, and irradiation impaired cued fear conditioning while ACP-105 enhanced fear conditioning in sham-irradiated and irradiated mice. The same paper reported a brain-region-specific interaction between ACP-105 treatment and a marker of neuronal structure (microtubule-associated protein 2) in the cortex of sham-irradiated animals.

A second paper, described in secondary sources as a 2013 study in ACS Chemical Neuroscience by George and colleagues, is reported to have examined non-steroidal SARMs and selective estrogen receptor beta agonists, including ACP-105, in a mouse model related to Alzheimer's disease pathology, against the general scientific background that declining testosterone and estrogen levels are associated with increased Alzheimer's disease risk in humans and animal models. This review was not able to independently verify the full content of that paper from a primary source and relies on a secondary summary; readers should treat the specific details of that study with corresponding caution until a primary citation can be confirmed.

Taken together, the published cognitive research on ACP-105 consists of a small number of exploratory studies using specific radiation-injury or disease models in mice, not evidence of a cognitive benefit in healthy humans. No human neurological or cognitive trial of ACP-105 has been published.

Has ACP-105 Been Tested in Humans?

No published, completed human clinical trial of ACP-105 was identified in this review. Independent compilations of the available literature likewise note that ACP-105 never advanced to published human clinical testing after Acadia's 2008 preclinical presentations, with no further company communications about the program afterward.

One secondary source references an early-stage clinical trial identifier associated with ACP-105 from the mid-2000s. This review could not verify that identifier against the ClinicalTrials.gov registry, and no results have been published in any form under that or any other identifier. This claim should therefore be treated as unconfirmed rather than as evidence that human trial data exist.

Separately, forensic and analytical chemistry work conducted for anti-doping purposes has examined how ACP-105 is metabolized when it is taken by humans outside of any clinical trial setting, presumably reflecting illicit use detected through doping-control testing. A 2023 comparison of in vitro and human in vivo metabolite data concluded that ACP-105 is metabolized to a high degree in humans, though the same paper noted that further studies with longitudinal sampling would be needed to characterize long-term metabolites. This is forensic metabolite characterization, not evidence of any studied clinical benefit or a controlled safety trial.

Consistent with its unapproved status, vendors selling ACP-105 label it for research use only and state it is not approved by the FDA for human use, reflecting its status as an unapproved investigational compound rather than a drug with any established human dosing or safety data.

Is ACP-105 Legal, and Is It Banned in Sports?

SARMs as a class, including ACP-105, are prohibited under the World Anti-Doping Agency's Prohibited List, where they have been classified in the "other anabolic agents" category since 2008.

ACP-105 specifically has been the subject of multiple analytical chemistry papers aimed at detecting it and its metabolites in doping control samples. Papers have reported detection and identification of ACP-105 and its metabolites in equine urine following oral administration, a 2021 study that tentatively identified 21 metabolites of ACP-105 from in vivo and in vitro experiments intended to improve doping-control detection in horses, and a 2023 follow-up comparing those in vitro-derived metabolites with metabolites detected in human samples. This body of work is explicitly framed around building better detection methods for regulated and illicit use, not around characterizing any therapeutic effect.

In the United States, products marketed as containing SARMs are treated by the FDA as unapproved drugs rather than lawful dietary supplements, a position the agency has communicated repeatedly in relation to the SARM class as a whole. ACP-105 falls under this same class-wide regulatory treatment, consistent with the vendor labeling that describes it as being for research use only and not approved by the FDA for human use.

What Are the Safety Risks?

There is no published, compound-specific human safety dataset for ACP-105 from a controlled clinical study. A 2025 paper in Archives of Toxicology that modeled its toxicological profile stated plainly that its safety profile remains insufficiently explored, particularly regarding its toxicity in humans, and explained that a lack of information about the compound at the World Anti-Doping Agency was the stated motivation for conducting the analysis.

That same research group, along with a related 2025 paper focused specifically on absorption, distribution, metabolism, and excretion (ADME), used multiple computational prediction platforms rather than measurements in living humans or animals. The ADME modeling projected high gastrointestinal absorption, moderate lipophilicity (LogP roughly 3.0 to 3.5), low aqueous solubility, and a substantial probability of blood-brain barrier penetration, alongside strong predicted plasma protein binding. The metabolism component of this modeling focused on interactions with cytochrome P450 enzymes and used computational tools to predict likely phase I and phase II metabolic pathways, rather than measuring actual enzyme-specific metabolism in humans. Because these figures are model predictions, they should not be read as confirmed pharmacokinetic values.

In the absence of compound-specific human safety data, the only broadly applicable safety context is the general regulatory position that SARMs as an unapproved drug class carry uncharacterized risks, and that products in this category are frequently sold without the warning labels a regulated pharmaceutical would carry, which can lead buyers to underestimate the risk involved. The absence of dedicated human safety studies for ACP-105 is itself a reason for caution, not a basis for assuming the compound is safer than other unapproved SARMs simply because it has been studied less.

Frequently asked

References